Apogee Therapeutics (APGE) EBIT (2022 - 2026)
Apogee Therapeutics (APGE) posted quarterly EBIT of -$82.8 million for Q1 2026, down 31.18% year-over-year from -$120.3 million in Q1 2025, and down 6.04% quarter-over-quarter from -$78.1 million in Q4 2025.
Powered by 
Analysis
Apogee Therapeutics (APGE) EBIT (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported EBIT for 5 consecutive years, with -$82.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 31.18% year-over-year to -$82.8 million; the TTM figure through Mar 2026 stood at -$305.3 million (down 26.26% YoY), while the FY2025 annual figure was -$285.6 million, down 31.69% from the prior year.
- EBIT fell to -$82.8 million in Q1 2026 per APGE's latest filing, from -$78.1 million in the prior quarter.
- Across five years, EBIT topped out at -$1.8 million in Q2 2022 and bottomed at -$82.8 million in Q1 2026.
- Historically, EBIT has averaged -$44.0 million across 5 years, with a median of -$41.2 million in 2024.
- Annual changes were most pronounced in 2023 — EBIT plunged 939.92% — and 2025, when it decreased 2.87%.
- Apogee Therapeutics' EBIT stood at -$14.1 million in 2022, then tumbled by 163.53% to -$37.2 million in 2023, then sank by 104.23% to -$75.9 million in 2024, then fell by 2.87% to -$78.1 million in 2025, then declined by 6.04% to -$82.8 million in 2026.
- Business Quant data shows APGE's EBIT at -$82.8 million in Q1 2026, -$78.1 million in Q4 2025, and -$71.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.72 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.56 Bn | 58.38 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.87 Bn | 52.73 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.08 Bn | 34.98 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.20 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.54 Bn | 27.70 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Apogee Therapeutics | 10.18 Bn | 9.20 Bn | - | -96.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -96.00 Mn |
| Mar 31, 2026 | -82.77 Mn |
| Dec 31, 2025 | -78.06 Mn |
| Sep 30, 2025 | -71.28 Mn |
| Jun 30, 2025 | -73.17 Mn |
| Mar 31, 2025 | -63.10 Mn |
| Dec 31, 2024 | -75.88 Mn |
| Sep 30, 2024 | -58.69 Mn |
| Jun 30, 2024 | -44.12 Mn |
| Mar 31, 2024 | -38.18 Mn |
| Dec 31, 2023 | -37.16 Mn |
| Sep 30, 2023 | -24.31 Mn |
| Jun 30, 2023 | -18.89 Mn |
| Mar 31, 2023 | -12.66 Mn |
| Dec 31, 2022 | -14.10 Mn |
| Sep 30, 2022 | -10.51 Mn |
| Jun 30, 2022 | -1.82 Mn |